Group 1 - The document does not contain any relevant information regarding companies or industries [1][2][3][4][5][6]

I want to get to a move that you have as well uh in the best performing sector of the quarter which is healthcare. So you got the news today on the FDA approving the first GLP-1 pill uh from Novo. You like animal health you have and you bought more Zoetas.Tell us why. >> Do you know it's been uh not since March of 2021 where this stock Zoetas has traded at a discounted multiple to Elanco. Now congrats to Lanco.I happen to own it but it's up 81%. It's a turnaround story. I'm inclined to take more profits the ...

Core Insights - Zoetis reported adjusted income of $1.70 per share on $2.4 billion in third-quarter sales, which was below analysts' expectations of $1.62 per share and $2.41 billion in sales [1][2] - The company maintained its adjusted profit guidance for $6.30 to $6.40 per share but cut its sales outlook to $9.4 billion to $9.475 billion, down from previous guidance of $9.45 billion to $9.6 billion [2] - In premarket trading, Zoetis stock fell 12.6% to $126.10, marking the lowest price since November 2022 [3] Financial Performance - Adjusted income for the year-earlier period was $1.58 per share with sales of $2.39 billion [1] - The new sales outlook represents organic operational growth of 5.5% to 7%, a decrease from the previous guidance of 6.5% to 8% [2] - Analysts had projected earnings of $6.35 per share and $9.51 billion in sales, indicating a potential shortfall in expectations [2] Market Reaction - The significant drop in stock price reflects investor concerns over the revised sales outlook and overall market conditions [3] - The decline in stock price to $126.10 indicates a negative market sentiment towards Zoetis following the earnings report [3]